In Section A, members will receive distinctive doses and schedules of oral ABBV-744 tablet to discover safe dosing regimen. Added contributors will likely be enrolled within the identified monotherapy dosign regimen. In Phase B, contributors will receive oral ruxolitinib and ABBV-744 will likely be specified as "add-on" therapy. In Segment https://brd4-targeted-therapy-abb24535.blogspothub.com/31358665/5-essential-elements-for-abbv-744-drug-development-progress-and-timeline